BAYER AG S/ADR (BAYRY) news covers developments at Bayer AG, a global life science enterprise active in health care and nutrition. Company communications highlight updates across its Pharmaceuticals Division, radiology business and crop science activities, giving investors and observers insight into how Bayer advances its pipeline and product portfolio.
Recent pharmaceutical news emphasizes growth in oncology, cardiology, neurology, immunology and women’s health. Examples include updates on asundexian for secondary stroke prevention, finerenone (Kerendia) in cardiovascular-kidney-metabolic conditions, and oncology assets such as Nubeqa for prostate cancer, Hyrnuo for HER2-mutant non-small cell lung cancer, and Xofigo for metastatic castration-resistant prostate cancer with bone metastases. Bayer also reports on Lynkuet, a hormone-free treatment for moderate to severe hot flashes due to menopause, and a Phase III SUNFLOWER study evaluating Mirena for nonatypical endometrial hyperplasia.
News items also describe Bayer’s work in radiology and molecular imaging, including the low-dose MRI contrast agent gadoquatrane and the acquisition of investigational tracers AT-01 and AT-05 for diagnosing cardiac amyloidosis. Additional coverage highlights cell and gene therapy programs for Parkinson’s disease and ophthalmic conditions, as well as collaborations such as the agreement with Soufflé Therapeutics to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy.
On the agriculture side, Bayer Crop Science Canada announcements feature launches like Sivanto Energy for flea beetle control in canola and EverGol Rise for pulse disease control. Together, these updates illustrate how Bayer seeks to execute its mission “Health for all, Hunger for none” through pharmaceutical innovation, diagnostic imaging advances and crop protection solutions.
Bayer (OTC:BAYRY) announced on March 4, 2026 that the U.S. FDA granted 510(k) clearance expanding the MEDRAD® MRXperion MR Injection System to support MRI scanners up to 7T field strength and adding Imaging Scanner Interface 2 (ISI2) to synchronize injector and scanner workflow.
The clearance aims to broaden MRXperion’s use across routine clinical and advanced research MR environments and strengthens Bayer’s integrated MR portfolio of contrast media, injection systems, software, and workflow solutions.
Bayer (OTC:BAYRY) presented first clinical data for 225Ac-PSMA-Trillium (BAY 3563254), an investigational targeted alpha therapy for advanced metastatic castration-resistant prostate cancer (mCRPC), at the 2026 ASCO Genitourinary Cancers Symposium (Feb 26-28, 2026). The Phase I PAnTHa study identified a dose for expansion with ≥80% PSA50 at that expansion dose, supporting advancement to the next clinical phase. The molecule uses actinium-225 linked to a PSMA-targeting small molecule with an albumin-binding moiety to increase tumor uptake. Data are preliminary and from a first-in-human dose-escalation trial.
Bayer (OTC: BAYRY) reported final PEACE-3 Phase III results showing XOFIGO (radium-223) plus enzalutamide reduced risk of death by 24% (HR 0.76; 95% CI 0.60–0.96; p=0.0096) and extended median overall survival to 38.2 months versus 32.6 months with enzalutamide alone.
The combination also improved radiological progression-free survival (rPFS 19.4 vs. 16.4 months; HR 0.69; p=0.0009). Grade ≥3 treatment-emergent adverse events occurred in 69% vs. 58% of patients. Results presented at ASCO GU 2026 and published simultaneously in Annals of Oncology.
Summary not available.
Bayer (OTC:BAYRY) launched the Heart to Heart Bistro, an immersive dark dining experience with Celebrity Chef Jeff Mauro for American Heart Month on Feb 2026. The campaign ties to the See Your Risks initiative and invites residents of NY, NJ, CT and PA to enter a sweepstakes by completing a 2-minute Heart Health Risk Assessment at SeeYourRisks.com.
The experience uses blindfolded, three-course dining to highlight unseen cardiovascular risk factors and encourage conversations with healthcare professionals.
Bayer (BAYRY) reported that in the global Phase III OCEANIC-STROKE trial, once-daily oral asundexian 50mg reduced recurrent ischemic stroke by 26% (csHR 0.74; 95% CI 0.65–0.84; p<.0001) versus placebo, with no increase in ISTH major bleeding (1.9% vs. 1.7%; HR 1.10).
OCEANIC-STROKE enrolled 12,327 patients and showed consistent benefit across age, sex, stroke subtype, NIHSS, and antiplatelet strategies; asundexian retains Fast Track designation by FDA and remains investigational.
Bayer (OTC: BAYRY) launched the “Highlights REAL” campaign with former quarterback Tony Romo and his father Ramiro to raise awareness of advanced prostate cancer and treatment management. The campaign encourages patients and caregivers to discuss treatment options, including NUBEQA (darolutamide), with their doctor and directs audiences to HighlightsREAL.com. Tony and Ramiro were compensated and are not NUBEQA patients. The release includes important safety information and directs readers to full prescribing information.
Bayer (OTC:BAYRY) announced an investment of more than $45 million CAD to build a canola innovation centre in Winnipeg, Manitoba to strengthen canola R&D in Canada. The centre will support seed development for canola, camelina and winter canola with work on trait integration, yield trial seed processing and seed quality analysis.
Design begins in 2026 with the facility expected to be operational by the end of 2028. The site will consolidate some breeding and seed generation activities while existing Smartpark and Carman sites maintain early breeding workflows and multi-crop nursery operations.
Bayer (OTC:BAYRY) will present main results and a prespecified subgroup analysis from the global Phase III OCEANIC-STROKE trial of asundexian, an investigational once-daily oral Factor XIa inhibitor, during two late-breaking sessions at the International Stroke Conference 2026 in New Orleans on February 4-6, 2026.
The multicenter, randomized, placebo-controlled, double-blind study enrolled >12,300 patients and, according to Bayer, met its primary efficacy and safety endpoints in November 2025.
Bayer (OTC: BAYRY) and Vanderbilt University Medical Center agreed a strategic five-year collaboration to accelerate discovery and development of therapies from target identification through Investigational New Drug (IND) application.
The partnership initially targets cardiovascular and kidney diseases, and will leverage VUMC’s BioVU DNA and plasma datasets and VUMC clinical/preclinical expertise combined with Bayer’s drug discovery and translational capabilities to enable data-driven insights and speed development of precision medicines.